Search results
Novartis to pay up to $1.75 billion for U.S. cancer-focused biotech
Market Watch· 2 days agoPharmaceutical giant Novartis AG on Thursday said it will pay up to $1.75 billion for a U.S. biotech...
Why selling to Novartis made sense for Mariana
BioPharma Dive via Yahoo Finance· 23 hours agoThat distinguishes its deal with Novartis from other recent acquisitions of RayzeBio by Bristol Myers Squibb and of Fusion Pharmaceuticals by AstraZeneca...
Novartis to buy Mariana Oncology in radiopharmaceutical expansion
BioPharma Dive via Yahoo Finance· 2 days agoNovartis currently sells two approved radiopharmaceuticals, Pluvicto and Lutathera. Their success...
Novartis to Buy Mariana Oncology for Up to $1.75 Billion in Boost to Radioligand Therapy Business
Morningstar· 2 days agoBy Mauro Orru Novartis agreed to acquire U.S. biotechnology company Mariana Oncology for up to $1.75 billion, in a deal that bolsters its radioligand therapy pipeline and ...
Novartis Is Tracking Well Above the Industry
GuruFocus.com via Yahoo Finance· 3 days agoNovartis AG (NYSE:NVS) is one of the largest pharmaceutical companies in the world, many of whose drugs are "gold standards" in the treatment of cancer,...
The top pharmaceutical companies by R&D expenditure
Pharmaceutical Technology via Yahoo Finance· 2 days agoLast year, major pharmaceutical companies heavily invested in R&D, with expenditure ranging from around 14% to 50% of their revenues. Some of the...
Novartis pays PeptiDream $180M as radiopharma big bang continues
FierceBiotech· 4 days agoNovartis is pumping another $180 million into its radioligand plan, handing the cash to serial dealmaker PeptiDream to expand (PDF) a peptide-drug conjugate (PDC) collaboration ...
FTC Targets ‘Junk’ Patent Listings on Ozempic and Other Drugs
The Wall Street Journal· 4 days agoAlso on the list are inhalers and more diabetes treatments from AstraZeneca Boehringer Ingelheim,...
FTC challenges 'junk' patents held by 10 drugmakers, including for Novo Nordisk's Ozempic
CNBC· 4 days agoThe Federal Trade Commission on Tuesday said it is challenging hundreds of alleged "junk" patents...
MorphoSys Says Novartis Deal Progressing Steadily Despite Safety Concerns Over Bone Marrow Cancer...
Benzinga· 5 days agoMorphoSys AG MOR is reportedly facing a burgeoning safety concern surrounding pelabresib, an...
